Search

Your search keyword '"Korobelnik, J-F"' showing total 458 results
Start Over Author "Korobelnik, J-F"
458 results on '"Korobelnik, J-F"'

1. Prise en charge de la toxoplasmose oculaire en France : résultats d’une étude Delphi modifiée

Author

Schaeffer, M., Ballonzoli, L., Gaucher, D., Arndt, C., Angioi-Duprez, K., Baudonnet, R., Bodaghi, B., Bron, A., Chiambaretta, F., Cimon, B., Chiquet, C., Creuzot-Garcher, C., Daien, V., Deleplanque, A.-S., Fricker-Hidalgo, H., Hadjadj, E., Houze, S., Ifrah, T., Korobelnik, J.-F., Labalette, P., Le Lez, M.-Laure, L’Ollivier, C., Mercie, M., Mouriaux, F., Paris, L., Pelloux, H., Pomares, C., Quintyn, J.-C., Rougier, M.-B., Rousseau, A., Soler, V., Talmud, M., Villena, I., Villard, O., Speeg-Schatz, C., Bourcier, T., and Sauer, A.

Published
2022
Full Text
View/download PDF

10. Comparaison des moyens clinique et d’imagerie disponibles en pratique clinique pour objectiver la présence de l’implant d’acétonide de fluocinolone (Iluvien®) dans la cavité vitréenne après injection

Author

Jomaa, E., primary, Koudsié, S., additional, Gontier, B., additional, Rougier, M.-B., additional, Gattoussi, S., additional, Seguy, P.-H., additional, Azar, M., additional, Korobelnik, J.-F., additional, and Delyfer, M.-N., additional

Published
2023
Full Text
View/download PDF

28. Recommendations for OCT Angiography Reporting in Retinal Vascular Disease: A Delphi Approach by International Experts.

Author

Munk, MR, Kashani, AH, Tadayoni, R, Korobelnik, J-F, Wolf, S, Pichi, F, Koh, A, Ishibazawa, A, Gaudric, A, Loewenstein, A, Lumbroso, B, Ferrara, D, Sarraf, D, Wong, DT, Skondra, D, Rodriguez, FJ, Staurenghi, G, Pearce, I, Kim, JE, Freund, KB, Parodi, MB, Waheed, NK, Rosen, R, Spaide, RF, Nakao, S, Sadda, S, Vujosevic, S, Wong, TY, Murata, T, Chakravarthy, U, Ogura, Y, Huf, W, Tian, M, Munk, MR, Kashani, AH, Tadayoni, R, Korobelnik, J-F, Wolf, S, Pichi, F, Koh, A, Ishibazawa, A, Gaudric, A, Loewenstein, A, Lumbroso, B, Ferrara, D, Sarraf, D, Wong, DT, Skondra, D, Rodriguez, FJ, Staurenghi, G, Pearce, I, Kim, JE, Freund, KB, Parodi, MB, Waheed, NK, Rosen, R, Spaide, RF, Nakao, S, Sadda, S, Vujosevic, S, Wong, TY, Murata, T, Chakravarthy, U, Ogura, Y, Huf, W, and Tian, M

Abstract

PURPOSE: To develop a consensus nomenclature for reporting OCT angiography (OCTA) findings in retinal vascular disease (e.g., diabetic retinopathy, retinal vein occlusion) by international experts. DESIGN: Delphi-based survey. SUBJECTS, PARTICIPANTS, AND/OR CONTROLS: Twenty-five retinal vascular disease and OCTA imaging experts. METHODS, INTERVENTION, OR TESTING: A Delphi method of consensus development was used, comprising 2 rounds of online questionnaires, followed by a face-to-face meeting conducted virtually. Twenty-five experts in retinal vascular disease and retinal OCTA imaging were selected to constitute the OCTA Nomenclature in Delphi Study Group for retinal vascular disease. The 4 main areas of consensus were: definition of the parameters of "wide-field (WF)" OCTA, measurement of decreased vascular flow on conventional and WF-OCTA, nomenclature of OCTA findings, and OCTA in retinal vascular disease management and staging. The study end point was defined by the degree of consensus for each question: "strong consensus" was defined as ≥85% agreement, "consensus" as 80% to 84%, and "near consensus" as 70% to 79%. MAIN OUTCOME MEASURES: Consensus and near consensus on OCTA nomenclature in retinal vascular disease. RESULTS: A consensus was reached that a meaningful change in percentage of flow on WF-OCTA imaging should be an increase or decrease ≥30% of the absolute imaged area of flow signal and that a "large area" of WF-OCTA reduced flow signal should also be defined as ≥30% of the absolute imaged area. The presence of new vessels and intraretinal microvascular abnormalities, the foveal avascular zone parameters, the presence and amount of "no-flow areas," and the assessment of vessel density in various retinal layers should be added for the staging and classification of diabetic retinopathy. Decreased flow ≥30% of the absolute imaged area should define an ischemic central retinal vein occlusion. Several other items did not meet consensus requirements or were

Published
2022

39. Wirksamkeit von intravitrealem Aflibercept, unter Anwendung eines Treat-and-Extend-Regimes, bei Patienten mit Makulaödem nach retinalem Zentralvenenverschluss: Ergebnisse der CENTERA-Studie

Author

Eter, Nicole, Korobelnik, J.-F., Larsen, M., Bailey, C., Wolf, S., Schmelter, T., Allmeier, H., and Chaudhary, V.

Subjects
ddc: 610, 610 Medical sciences, Medicine
Abstract

Ziel: Wirksamkeit und Sicherheit von intravitrealem Aflibercept (IVT-AFL), unter Anwendung eines Treat-and-Extend-(T&E-)Regimes bei Patienten mit Makulaödem nach retinalem Zentralvenenverschluss (ZVV). Quelle der Daten CENTERA (NCT02800642) eine 76-wöchige multizentrische, unverblindete,[zum vollständigen Text gelangen Sie über die oben angegebene URL], 33. Jahrestagung der Retinologischen Gesellschaft

Published
2021

43. Effect of pegaptanib sodium 0.3□mg intravitreal injections (Macugen) in intraocular pressure: posthoc analysis from V.I.S.I.O.N. study

Author

Boyer, David S, Goldbaum, Mauro, Leys, Anita M, Starita, Carla, Blumenkranz, M, Buyse, M, Goldberg, M, Gragoudas, E S, Miller, J, Schwartz, S D, Singerman, L, Yannuzzi, L, Adamis, A P, Guyer, D R, OʼShaughnessy, D, de Gronckel, S, Fesneau, G, Quinaux, E, Tremolet, D, Wang, K, Brailey, A, Finman, J, Ting, N, Bressler, N M, Bressler, S B, Denblow, R, Schein, O D, Seabrook, S, Solomon, S, Schachat, A P, Philips, D, Altaweel, M, Davis, M D, Blodi, B A, Danis, R P, Ip, M S, Hiner, C, Elledge, J, Webster, M, Hannan, C, Ficken, J, Alexander, S, Neider, M, Wabers, H, Vargo, P, Lambert, E, Kastorff, L, Carr, A, Shkiele, A, Baliker, J, Guymer, R, Constable, I, Arnold, J, Sarks, S, Chang, A, Gillies, M, Mitchell, P, Haas, A, Stur, M, Leys, A, Moreira, C, Portella, E, de Avila, M, Taleb, A C, Lavinsky, J, Lavinsky, D, Farah, M E, Williams, G, Leonard, B, Garcia, R, Maberley, D, Lopez, J M, Rodriguez, F J, Fiser, I, Larsen, M, Korobelnik, J-F, Soubrane, G, Koenig, F, Gaudric, A, Dithmar, S, Holz, F G, Joussen, A, Kirchhof, B, Wiedemann, P, Pauleikhoff, D, Schneider, U, Suveges, I, Gyory, J, Pollack, A, Loewenstein, A, Rosenblatt, I, Giovannini, A, Menchini, U, Brancato, R, Piccolino, Cardillo F, Grignolo, F M, Bandello, F, Schlingemann, R O, Deutman, A, Kaluzny, J, Pecold, K, Cunha-Vaz, J, da Silva, R, Ruiz Moreno, J M, Mones, J, Figueroa, M, Pournaras, C, Zografos, L, Lois, N, Chakravarthy, U, Hykin, P, Chisholm, I, Johnson, M W, Marcus, D M, Mandava, N, Haller, J A, Cangemi, F, Boyer, D, Kim, I, Loewenstein, J, Heier, J, Reichel, E, Falcone, P M, Weissgold, D J, Conway, B P, Garfinkel, R, Glaser, B, Lyon, A T, Lewis, H, Wells, J A, Wilcox, L, Fish, G, Eliott, D, Fekrat, S, Taney, B, Eaton, A M, Deramo, V, Wroblewski, J, Tom, D, Chow, D R, Orth, D H, Packo, K H, Holz, E, Mieler, W, Kuppermann, B, Sabates, N, Cummings, H, Pendergast, S D, Gonzales, C, Lim, J I, Charles, S, Sanislo, S, Rosenfeld, P, Connor, T, Cantrill, H, Willson, R, Bailey-Freund, K, Rosen, R, Leonard, R, Brucker, A, Ho, A, Sneed, S, Friberg, T, Klein, M, Tornambe, P, Stoller, G, Capone, A, Jr, Bernstein, P S, McDonald, H R, Schatz, H, Johnson, R N, Nanda, M, Avery, R, Wong, K, Grizzard, W S, Higgins, P, Hudson, H, Joffe, L, Varenhorst, M, Slusher, M M, Betts, F, Cunningham, E, Jr, Curtiss, K, Harrison, E, Katz, B, Masonson, H N, DeMarco, R, Beals, C, Patel, M, Rodriguez, I, and Starita, C

Published
2014
Full Text
View/download PDF

44. Evolution of treatment paradigms in neovascular age-related macular degeneration: a review of real-world evidence

Author

Daien, V, Finger, RP, Talks, JS, Mitchell, P, Wong, TY, Sakamoto, T, Eldem, BM, Korobelnik, J-F, Daien, V, Finger, RP, Talks, JS, Mitchell, P, Wong, TY, Sakamoto, T, Eldem, BM, and Korobelnik, J-F

Abstract

The aim of this work was to evaluate the contribution of real-world evidence (RWE) in changing anti-vascular endothelial growth factor (VEGF) therapy treatment practices and improving real-world treatment strategies for neovascular age-related macular degeneration (nAMD).A PubMed literature search was performed to review the large number of English-language studies conducted to investigate the real-world effectiveness of anti-VEGF (aflibercept and ranibizumab) treatment paradigms available for nAMD.The evidence for pro re nata (PRN), treat-and-extend (T&E) and fixed bimonthly dosing regimens for anti-VEGF treatment of nAMD were reviewed and findings are summarised. RWE demonstrated that T&E regimens optimise visual outcomes while reducing burden on patients, clinics and physicians, compared with both fixed-dose and PRN regimens.RWE has helped to develop and improve real-world treatment strategies in nAMD, with the aim of optimising visual outcomes and reducing treatment burden in clinical practice. Of the various regimens, a T&E regimen is most likely to adequately balance clinical outcomes and treatment burden for patients with nAMD.

Published
2021

45. Rationale and Design for the Phase 3 Clinical Trials of Faricimab for Neovascular Age-Related Macular Degeneration

Author

Khanani, AM, Guymer, RH, Basu, K, Boston, H, Heier, JS, Korobelnik, J-F, Kotecha, A, Lin, H, Silverman, D, Swaminathan, B, Willis, JR, Yoon, YH, Quezada-Ruiz, C, Khanani, AM, Guymer, RH, Basu, K, Boston, H, Heier, JS, Korobelnik, J-F, Kotecha, A, Lin, H, Silverman, D, Swaminathan, B, Willis, JR, Yoon, YH, and Quezada-Ruiz, C

Abstract

PURPOSE: To describe the design and rationale of the phase 3 TENAYA (ClinicalTrials.gov identifier, NCT03823287) and LUCERNE (ClinicalTrials.gov identifier, NCT03823300) trials that aimed to assess efficacy, safety, and durability of faricimab, the first bispecific antibody for intraocular use, which independently binds and neutralizes both angiopoietin-2 and vascular endothelial growth factor-A (VEGF-A) versus aflibercept in patients with neovascular age-related macular degeneration (nAMD). DESIGN: Identical, global, double-masked, randomized, controlled, phase 3 clinical trials. PARTICIPANTS: Adults with treatment-naïve nAMD. METHODS: These trials were designed to evaluate patients randomized to receive faricimab 6.0 mg up to every 16 weeks after 4 initial every-4-week doses or aflibercept 2.0 mg every 8 weeks after 3 initial every-4-week doses. The initial doses in the faricimab arm were followed by individualized fixed treatment intervals up to week 60, based on disease activity assessment at weeks 20 and 24, guided by central subfield thickness, best-corrected visual acuity (BCVA), and investigator assessment. The primary efficacy end point was BCVA change from baseline averaged over weeks 40, 44, and 48. Secondary end points included the proportion of patients receiving every-8-week, every-12-week, and every-16-week faricimab and anatomic outcomes. Safety outcomes included incidence and severity of ocular and nonocular adverse events. From week 60, faricimab-treated patients followed a personalized treatment interval (PTI), a novel protocol-driven treat-and-extend regimen with interval adjustment from every 8 weeks to every 16 weeks based on individualized treatment response measured by anatomic criteria, functional criteria, and investigator assessment of patients' disease activity. MAIN OUTCOME MEASURES: Rationale for trial design and PTI approach. RESULTS: The TENAYA and LUCERNE trials were the first registrational trials in nAMD to test fixed dosing regime

Published
2021

48. Evolving European guidance on the medical management of neovascular age related macular degeneration

Author

Chakravarthy, U., Soubrane, G., Bandello, F., Chong, V., Creuzot-Garcher, C., Dimitrakos, S.A., II, Korobelnik, J.-F., Larsen, M., Mones, J., Pauleikhoff, D., Pournaras, C.J., Staurenghi, G., Virgili, G., and Wolf, S.

Subjects
Macular degeneration -- Care and treatment, Neovascularization -- Care and treatment, Choroid -- Diseases, Ophthalmology -- Practice, Medicine -- Practice, Medicine -- Standards, Health
Published
2006

Catalog

Books, media, physical & digital resources
See catalog results